Spruce Biosciences   Report issue

For profit Phase 2
Founded: San Francisco CA United States (2014)

Organization Overview

First Clinical Trial
2017
NCT03257462
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Spruce Biosciences

Active Ingredients

Drugs in Phase 2 Trials (1)

Tildacerfont (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenal Hyperplasia, Congenital (Phase 2)

Adrenocortical Hyperfunction (Phase 2)

Adrenogenital Syndrome (Phase 2)

Hyperplasia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 1